InMode (INMD) FCF Margin (2018 - 2026)

InMode (INMD) posted FCF Margin of 18.97% for Q1 2026, down 15.11% sequentially from 22.35% in Q4 2025, and up 83.0% YoY from 10.37% in Q1 2025.

InMode (INMD) FCF Margin (2018 - 2026) Analysis & Trends

InMode has reported FCF Margin for 9 years, with the latest figure at 18.97% in Q1 2026.

Quarterly FCF Margin rose 83.0% year-over-year to 18.97% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 23.4% (down 801.0% YoY) and the FY2025 annual result came in at 23.27%, down 1050.0% from the prior year.
FCF Margin eased to 18.97% in Q1 2026 per INMD's latest filing, from 22.35% in the prior quarter.
Over five years, FCF Margin peaked at 48.94% in Q2 2024 and troughed at 18.14% in Q1 2025.
A 5-year average of 32.45% and a median of 33.39% in 2024 frame the typical range for FCF Margin.
The sharpest annual moves came in 2024 and 2025: FCF Margin surged 995 bps in 2024, then plunged 2353 bps in 2025.
Over 5 years, FCF Margin stood at 43.03% in 2022, then advanced by 12 bps to 48.26% in 2023, then tumbled by 31 bps to 33.39% in 2024, then tumbled by 33 bps to 22.35% in 2025, then declined by 15 bps to 18.97% in 2026.
According to Business Quant data, FCF Margin over the past three periods registered 18.97%, 22.35%, and 26.41% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Abbott Laboratories	199.61 Bn	194.01 Bn	7.27 Bn	15.81%
2	Stryker	127.81 Bn	124.34 Bn	4.50 Bn	16.07%
3	Medtronic	119.04 Bn	109.82 Bn	6.41 Bn	21.26%
4	Boston Scientific	73.68 Bn	73.14 Bn	3.85 Bn	23.50%
5	Edwards Lifesciences	51.96 Bn	47.71 Bn	1.35 Bn	33.60%
6	Dexcom	34.36 Bn	32.41 Bn	830.00 Mn	14.10%
7	GE HealthCare Technologies	33.83 Bn	31.72 Bn	2.18 Bn	1.28%
8	Koninklijke Philips	26.36 Bn	23.04 Bn	4.55 Bn	5.32%
9	Steris	23.06 Bn	22.58 Bn	684.20 Mn	18.73%
10	InMode	911.60 Mn	496.43 Mn	71.52 Mn	22.24%

Download Data